COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age

Key Inclusion Criteria:

1. Is <12 years of age and ≥3 kg to <40 kg at the time parental/guardian consent issigned
2. Has at least one risk factor for developing severe COVID-19 if they were to becomeinfected, such as:
3. Obesity (BMI [kg/m2] ≥95th percentile for age and sex based on CDC growth charts)
4. Cardiovascular disease
5. Chronic lung disease
6. Type 1 or type 2 diabetes mellitus
7. Chronic kidney disease, including those on dialysis
8. Chronic liver disease
9. Immunocompromised or immunodeficient, based on Investigator's assessment (examples include cancer treatment, bone marrow or organ transplantation, immunedeficiencies, HIV infection, sickle cell anemia, thalassemia, and prolonged useof immune-weakening medications)
10. Medical complexities (examples include any underlying genetic condition,neurologic condition, metabolic condition, or congenital heart disease)
11. Any other condition deemed by the Investigator to be a risk factor for severeCOVID-19

Key Exclusion Criteria:

1. Has positive diagnostic test for SARS-CoV-2 infection from a sample collected duringscreening ≤7 days prior to study drug administration Note: The sample for the testshould be collected ≤7 days within study drug administration, and the result should bereviewed and confirmed negative prior to dosing. Historical records will not beaccepted.
2. Has active respiratory or non-respiratory symptoms consistent with COVID-19 in theopinion of the Investigator
3. Has subject-reported clinical history of COVID-19, as determined by Investigator,within the last 90 days
4. Has subject-reported history of prior Emergency Use Authorization (EUA)/approvedpositive diagnostic test for SARSCoV-2 infection within the last 90 days
5. Is currently hospitalized or was hospitalized for >24 hours for any reason within 14days of the screening visit
6. Prior use (within 90 days prior to study drug administration) or current use of anyinvestigational, authorized, or approved passive antibody for prophylaxis ofSARS-CoV-2 infection, including convalescent plasma, convalescent sera, hyperimmuneglobulin, or other monoclonal antibodies (eg, bamlanivimab and etesevimab, sotrovimab)
7. Has initiated vaccination for SARS-CoV-2 with an investigational or approved vaccine,but has not completed the vaccine schedule as recommended by the vaccine manufacturer.
8. Plans to receive an investigational or approved SARS-CoV-2 vaccine within 90 daysafter study drug administration, or per the recommended time frame from the currentCenters for Disease Control vaccination guidelines (CDC, 2021b) NOTE: Other protocol-defined Inclusion/ Exclusion Criteria apply